Zensar Technologies Ltd Share Price – NSE /  BSE

IT - Software, Small Cap

Zensar Technologies announced that ICRA Limited has re-affirmed long-term rating at [ICRA] AA+ and short-term rating at [ICRA] A1+. Further, the outlook on the long-term rating has been maintained as stable.

Powered by Capital Market - Live News

However, revenue from operations grew by 4.74% quarter on quarter (QoQ) to Rs 1,288.1 crore in Q1 FY25.

On year on year (YoY) basis, the IT firm’s net profit fell 9.96% while revenue grew 4.96% in Q1 FY25.

Profit before tax stood at Rs 209.7 crore crore in quarter ended 30 June 2024, registered growth 8.26% QoQ.

EBITDA stood at Rs 196.1 crore in Q1 FY25, down 3.4% QoQ and 14.8% YoY. EBITDA margin declined to 15.2% in Q1 FY25 as against 16.5% recorded in Q4 FY24 and 18.7% reported in Q1 FY24.

In Q1 FY25, the company reported revenue of $154.4 million, sequential QoQ growth of 4.2% in reported currency and 4.3% in constant currency.

US region reported a QoQ revenue growth of 6.5% in reported currency and 6.6% in constant currency.

Banking and Financial Services (BFSI) reported a sequential services revenue growth of 6.8% in both reported and constant currency.

Manufacturing and Consumer Services reported a QoQ service revenue growth of 2.4% in reported currency and 2.7% in constant currency.

The company reported net cash of $280.9 million at the end of Q1FY25, recorded a growth of 7.3% QoQ.

Manish Tandon, CEO and managing director, Zensar, said,Our disciplined approach on execution helped us to improve cash and cash equivalents to $280.9M, QoQ addition of 19.2M. Sequentially, we have improved our DSO by 1 day to 72 days. Our order book stood at $154.0M and PAT at 12.3% for the quarter.

We continue to stay focused on growth & cost optimization to maintain robust financial performance.”

Zensar Technologies is a globally focused software and services company spread across eighteen countries across the world. Zensar provides end–to–end services from IT development to Business Process Outsourcing, from consulting to implementation. The company is headquartered in Pune, India, our 10,300+ employees work across 30+ locations, including San Jose, Seattle, Princeton, Cape Town, London, Singapore, and Mexico City.

The scrip rose 1.76% to Rs 761.55 on the BSE.

Powered by Capital Market - Live News

Net profit of Zensar Technologies rose 1.09% to Rs 157.90 crore in the quarter ended June 2024 as against Rs 156.20 crore during the previous quarter ended June 2023. Sales rose 4.96% to Rs 1288.10 crore in the quarter ended June 2024 as against Rs 1227.20 crore during the previous quarter ended June 2023.

Powered by Capital Market - Live News

Zensar Technologies announced today the full acquisition of BridgeView Life Sciences LLC. The US]based leader in information technology and operations provides a comprehensive range of advisory, transformation, and managed services exclusively for life sciences customers endeavoring to launch products or new indications, assess and optimize their operations, or engage in merger or acquisition transactions. This strategic move strengthens Zensar's Healthcare and Life Sciences (HLS) vertical and expands its pharma commercial and product launch expertise.

The acquisition positions Zensar to offer a more comprehensive suite of solutions to pharmaceutical, biotechnology, and medical device companies. BridgeView's Preferred Services Partner and Services Partner status with Veeva Systems' Commercial Cloud and Development Cloud, respectively, solidify Zensar's position as a trusted technology partner. Additionally, BridgeView's partnerships with Reltio, Datavant, Snowflake, Salesforce, and IQVIA bolster its capabilities.

Powered by Capital Market - Live News